MX337468B - Anticuerpos anti notch-1. - Google Patents
Anticuerpos anti notch-1.Info
- Publication number
- MX337468B MX337468B MX2011013717A MX2011013717A MX337468B MX 337468 B MX337468 B MX 337468B MX 2011013717 A MX2011013717 A MX 2011013717A MX 2011013717 A MX2011013717 A MX 2011013717A MX 337468 B MX337468 B MX 337468B
- Authority
- MX
- Mexico
- Prior art keywords
- epitope
- antibodies
- notch1
- nrr
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a un método para preparar una masa de pan fermentada, el método comprende la siguiente secuencia de pasos de procesamientos: a) combinar harina, agua, levadura y/o agente de fermentación y opcionalmente uno o más ingredientes de panadería adicionales para producir una mezcla de tipo masa; b) mezclar y trabajar la mezcla de tipo masa en una mezclador a para producir una masa subdesarrollada con una densidad de 0.9-1.5 g/ml, la entrada de energía total de la mezcladora en la masa subdesarrollada durante el mezclado y el trabajo de la mezcla de tipo masa es por lo menos 1 W.h/Kg; c) trabajar adicionalmente un lote de por lo menos 15 kg de masa subdesarrollada al someterla a esfuerzo cortante de deformación, produciendo de ese modo una masa desarrollada; d) dividir la masa desarrollada en dos o más piezas de masa desarrollada que tienen una masa individual de 30-3000 g; y e) fermentar las piezas de masa desarrollada para generar piezas de masa fermentada que tienen un volumen específico de por lo menos 2.0 ml/g; en donde la secuencia mencionada anteriormente de pasos de procesamiento se completa dentro de 3 horas. El presente proceso emplea trabajo de alta energía para producir una masa subdesarrollada, seguido de trabajo de baja energía para desarrollar adicionalmente la masa. Al emplear una combinación de trabajo de alta energía y trabajo de baja energía, la energía de trabajo total necesaria para la preparación de una masa completamente desarrollada se puede reducir sustancialmente. Al mismo tiempo, esta combinación de condiciones de trabajo produce una masa que después del horneado genera una migaja muy suave con una estructura de migaja extremadamente regular. La invención proporciona además una barra de pan de mole que tiene una estructura celular única que se puede obtener por medio del método mencionado anteriormente, así como también un aparato para operar el método mencionado anteriormente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21819309P | 2009-06-18 | 2009-06-18 | |
| PCT/IB2010/052711 WO2010146550A1 (en) | 2009-06-18 | 2010-06-16 | Anti notch-1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011013717A MX2011013717A (es) | 2012-05-29 |
| MX337468B true MX337468B (es) | 2016-03-02 |
Family
ID=42575817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011013717A MX337468B (es) | 2009-06-18 | 2010-06-16 | Anticuerpos anti notch-1. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9090690B2 (es) |
| EP (2) | EP3431501A1 (es) |
| JP (2) | JP6059985B2 (es) |
| KR (1) | KR101570898B1 (es) |
| CN (1) | CN102686610A (es) |
| AU (1) | AU2010261364B2 (es) |
| BR (1) | BRPI1011805A2 (es) |
| CA (1) | CA2765989C (es) |
| CO (1) | CO6480924A2 (es) |
| IL (1) | IL217066A0 (es) |
| MX (1) | MX337468B (es) |
| NZ (1) | NZ597611A (es) |
| PE (1) | PE20121494A1 (es) |
| PH (1) | PH12011502609B1 (es) |
| RU (1) | RU2011151287A (es) |
| SG (1) | SG176731A1 (es) |
| WO (1) | WO2010146550A1 (es) |
| ZA (1) | ZA201109282B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009298569A1 (en) * | 2008-10-01 | 2010-04-08 | Genentech, Inc. | Anti-Notch2 antibodies and methods of use |
| PE20121494A1 (es) * | 2009-06-18 | 2012-11-01 | Pfizer | Anticuerpos anti notch-1 |
| CA2775880A1 (en) * | 2009-09-30 | 2011-04-07 | Genentech, Inc. | Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias |
| MX346995B (es) | 2010-12-15 | 2017-04-06 | Wyeth Llc | Anticuerpos anti-notch1. |
| WO2012080891A1 (en) * | 2010-12-15 | 2012-06-21 | Rinat Neuroscience Corp. | Anti-notch-1 antibodies |
| KR20150082548A (ko) | 2012-11-07 | 2015-07-15 | 화이자 인코포레이티드 | 항-notch3 항체 및 항체-약물 접합체 |
| CA2941733A1 (en) * | 2014-03-07 | 2015-09-11 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with notch1 antibodies |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| US11026996B2 (en) * | 2016-05-25 | 2021-06-08 | The Trustees Of Columbia University In The City Of New York | Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling |
| JP2019535250A (ja) * | 2016-10-29 | 2019-12-12 | ジェネンテック, インコーポレイテッド | 抗mic抗体及び使用方法 |
| JP7525160B2 (ja) | 2018-08-31 | 2024-07-30 | Bloom Technology 株式会社 | 終末糖化産物に対する抗体およびその使用 |
| EP4585226A1 (en) | 2022-09-09 | 2025-07-16 | Institute Of Science Tokyo | Therapeutic agent for coronavirus infection |
| CN121319198A (zh) * | 2025-04-14 | 2026-01-13 | 北京光辉天成生物科技有限公司 | 一种高亲和力padi2抗体及其制备方法 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| GB8421551D0 (en) | 1984-08-24 | 1984-09-26 | Ici Plc | Water-soluble dye |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| JP2698529B2 (ja) | 1993-04-06 | 1998-01-19 | 浜松ホトニクス株式会社 | イメージインテンシファイア装置 |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU768269B2 (en) | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
| US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| WO2002059285A1 (en) * | 2000-10-27 | 2002-08-01 | Fred Hutchinson Cancer Research Center | Methods for immortalizing cells |
| US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
| US20030148954A1 (en) * | 2001-11-02 | 2003-08-07 | Wisconsin Alumni Research Foundation | Agents and methods for modulating activator protein-1-mediated cellular processes |
| AU2002339157A1 (en) | 2001-11-14 | 2003-05-26 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
| CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| JP4558485B2 (ja) | 2002-07-18 | 2010-10-06 | 正康 大河内 | Notch由来新規ポリペプチドおよびそれを用いたバイオマーカー並びに試薬 |
| CN102746399B (zh) | 2002-12-24 | 2016-03-02 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| AU2004294563B2 (en) | 2003-11-26 | 2009-03-26 | Health Research, Inc. | Use of notch pathway interfering agents for treatment of plasma cell disorders |
| US20080220416A1 (en) | 2004-05-20 | 2008-09-11 | The Board Of Trustees Of The University Of Illinoi | Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof |
| US20070077245A1 (en) | 2004-08-04 | 2007-04-05 | The Brigham And Women's Hospital, Inc. | NOTCH mutations leading to increased receptor signaling |
| WO2006053063A2 (en) | 2004-11-05 | 2006-05-18 | The Regents Of The University Of California | Notch-1 assay to detect neurodegenerative diseases |
| WO2006068953A2 (en) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| US20080206753A1 (en) | 2005-03-04 | 2008-08-28 | The Hospital For Sick Children | Methods for Cancer Prognosis |
| US7100777B1 (en) * | 2005-07-07 | 2006-09-05 | Jui-Chien Kao | Hanger rack for hand tools |
| US20070072222A1 (en) | 2005-09-23 | 2007-03-29 | Franziska Boess | FABP4 as biomarker for toxic effect |
| US20090305310A1 (en) | 2005-11-22 | 2009-12-10 | University Of Vermont And State Agricultural College | Methods for Determining Notch Signaling and Uses Thereof |
| US20080241150A1 (en) | 2006-05-15 | 2008-10-02 | The Brigham And Women's Hospital, Inc. | Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1 |
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| EP2134356A2 (en) | 2007-03-05 | 2009-12-23 | Board of Regents, The University of Texas System | Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy |
| PE20090321A1 (es) * | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| US8119366B2 (en) | 2007-10-05 | 2012-02-21 | Trojan Technologies, Ltd. | Antennapedia-dominant negative mastermind-like construct |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2307051B1 (en) | 2008-07-08 | 2015-02-11 | OncoMed Pharmaceuticals, Inc. | Notch-binding agents and antagonists and methods of use thereof |
| WO2010059543A1 (en) | 2008-11-20 | 2010-05-27 | Merck Sharp & Dohme Corp. | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
| PE20121494A1 (es) * | 2009-06-18 | 2012-11-01 | Pfizer | Anticuerpos anti notch-1 |
| CA2775880A1 (en) | 2009-09-30 | 2011-04-07 | Genentech, Inc. | Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias |
| WO2011088215A2 (en) | 2010-01-13 | 2011-07-21 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| WO2012080891A1 (en) | 2010-12-15 | 2012-06-21 | Rinat Neuroscience Corp. | Anti-notch-1 antibodies |
| MX346995B (es) | 2010-12-15 | 2017-04-06 | Wyeth Llc | Anticuerpos anti-notch1. |
-
2010
- 2010-06-16 PE PE2011002114A patent/PE20121494A1/es not_active Application Discontinuation
- 2010-06-16 NZ NZ597611A patent/NZ597611A/en not_active IP Right Cessation
- 2010-06-16 EP EP18172657.1A patent/EP3431501A1/en not_active Withdrawn
- 2010-06-16 RU RU2011151287/10A patent/RU2011151287A/ru not_active Application Discontinuation
- 2010-06-16 CN CN2010800367326A patent/CN102686610A/zh active Pending
- 2010-06-16 JP JP2012515616A patent/JP6059985B2/ja not_active Expired - Fee Related
- 2010-06-16 CA CA2765989A patent/CA2765989C/en not_active Expired - Fee Related
- 2010-06-16 KR KR1020127001293A patent/KR101570898B1/ko not_active Expired - Fee Related
- 2010-06-16 AU AU2010261364A patent/AU2010261364B2/en not_active Ceased
- 2010-06-16 PH PH1/2011/502609A patent/PH12011502609B1/en unknown
- 2010-06-16 WO PCT/IB2010/052711 patent/WO2010146550A1/en not_active Ceased
- 2010-06-16 EP EP10730230A patent/EP2443151A1/en not_active Withdrawn
- 2010-06-16 US US13/378,791 patent/US9090690B2/en active Active
- 2010-06-16 BR BRPI1011805A patent/BRPI1011805A2/pt not_active IP Right Cessation
- 2010-06-16 SG SG2011090800A patent/SG176731A1/en unknown
- 2010-06-16 MX MX2011013717A patent/MX337468B/es active IP Right Grant
-
2011
- 2011-12-15 ZA ZA2011/09282A patent/ZA201109282B/en unknown
- 2011-12-18 IL IL217066A patent/IL217066A0/en unknown
- 2011-12-22 CO CO11177186A patent/CO6480924A2/es active IP Right Grant
-
2016
- 2016-01-14 JP JP2016004952A patent/JP2016121162A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102686610A (zh) | 2012-09-19 |
| KR101570898B1 (ko) | 2015-11-23 |
| IL217066A0 (en) | 2012-02-29 |
| MX2011013717A (es) | 2012-05-29 |
| US20120093813A1 (en) | 2012-04-19 |
| AU2010261364B2 (en) | 2015-05-07 |
| PH12011502609B1 (en) | 2018-11-07 |
| BRPI1011805A2 (pt) | 2016-10-11 |
| CO6480924A2 (es) | 2012-07-16 |
| WO2010146550A1 (en) | 2010-12-23 |
| AU2010261364A1 (en) | 2012-01-19 |
| EP3431501A1 (en) | 2019-01-23 |
| CA2765989C (en) | 2016-11-29 |
| PH12011502609A1 (en) | 2012-11-12 |
| RU2011151287A (ru) | 2013-07-27 |
| NZ597611A (en) | 2014-03-28 |
| JP6059985B2 (ja) | 2017-01-11 |
| KR20120071379A (ko) | 2012-07-02 |
| CA2765989A1 (en) | 2010-12-23 |
| EP2443151A1 (en) | 2012-04-25 |
| SG176731A1 (en) | 2012-01-30 |
| US9090690B2 (en) | 2015-07-28 |
| JP2016121162A (ja) | 2016-07-07 |
| JP2012530487A (ja) | 2012-12-06 |
| ZA201109282B (en) | 2012-08-29 |
| PE20121494A1 (es) | 2012-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12011502609B1 (en) | Anti notch-1 antibodies | |
| NZ616382A (en) | Antibodies specific to cadherin-17 | |
| MX2024005976A (es) | Un anticuerpo anti-tigit, un anticuerpo anti-pvrig y un anticuerpo anti-pd-1 para usarse en el tratamiento de cancer. | |
| CL2014000574A1 (es) | Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. | |
| CR20170251A (es) | Anticuerpos anti-c5 y métodos para su uso | |
| MX362705B (es) | Anticuerpos monoclonales multiespecíficos. | |
| WO2013064701A3 (en) | Specific antibodies and their isolation with anti-idiotypic antibodies | |
| NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
| EA201390933A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
| NZ629913A (en) | Anti-ox40 antibodies and methods of using the same | |
| EP3702372A3 (en) | Anti-cd40 human antibodies | |
| BRPI1013428A2 (pt) | anticorpos humanizados para axl | |
| MX2020009634A (es) | Anticuerpos y metodos de uso. | |
| EP4368704A3 (en) | Cell | |
| MX374826B (es) | Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas. | |
| MX2016008187A (es) | Anticuerpos biespecificos anti-hapteno/anti-receptor de barrera hematoencefalica, complejos de los mismos y su uso como transportadores a traves de la barrera hematoencefalica. | |
| NZ586754A (en) | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof | |
| MX2014012978A (es) | Regiones de anticuerpo modificado y sus usos. | |
| EP3029069A4 (en) | Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof | |
| IL222359A0 (en) | Monoclonal antibodies against her2 antigens, and uses therefor | |
| NZ611785A (en) | Anti-notch1 antibodies | |
| WO2015051320A3 (en) | Anti-sox10 antibody systems and methods | |
| EP2971047A4 (en) | MONOCLONAL ANTIBODIES TO TRANSFERRIN AND TRANSFERRIN RECEPTOR ANTIGEN AND USES THEREOF | |
| WO2012149334A3 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |